Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of "Moderate Buy" by Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $93.33.

PBH has been the subject of a number of research analyst reports. Royal Bank of Canada increased their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research note on Friday, March 21st. Canaccord Genuity Group lifted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Oppenheimer upped their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Finally, DA Davidson upped their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday, February 7th.

Prestige Consumer Healthcare Stock Up 0.3 %

Shares of Prestige Consumer Healthcare stock opened at $81.25 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of 19.03, a PEG ratio of 2.69 and a beta of 0.44. The firm's 50-day moving average is $83.08 and its two-hundred day moving average is $81.11. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, research analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.60% of the company's stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds have recently bought and sold shares of the business. Kestra Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $27,000. CIBC Private Wealth Group LLC raised its position in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the period. Opal Wealth Advisors LLC purchased a new position in Prestige Consumer Healthcare during the first quarter valued at $38,000. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare during the fourth quarter valued at $40,000. Finally, McIlrath & Eck LLC grew its position in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after purchasing an additional 154 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.